# SVF for Treating Pulmonary Fibrosis Post COVID-19

> **NCT06304623** · PHASE1 · COMPLETED · sponsor: **Michael H Carstens** · enrollment: 40 (actual)

## Conditions studied

- Pulmonary Fibrosis

## Interventions

- **BIOLOGICAL:** Autologous adipose-derived SVF IV administration

## Key facts

- **NCT ID:** NCT06304623
- **Lead sponsor:** Michael H Carstens
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-05
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304623, "SVF for Treating Pulmonary Fibrosis Post COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06304623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*